Articles tagged with Bone Cancer
The Mayo Clinic study found that the risk of progression from MGUS to multiple myeloma or related cancers is approximately one percent per year, with larger M-protein levels increasing the risk. Patients with very small protein levels had a 14% progression rate at 20 years, while those with high levels had a 60% progression rate.
A Mayo Clinic study has confirmed the effectiveness of samarium as a treatment option for osteosarcoma, with 24 of 30 patients experiencing a good to excellent response. The radioactive drug targets tumors in the bone, killing off cancer cells and reducing side effects associated with chemotherapy.
Researchers found that 71% of women experienced ovarian function loss and rapid bone loss after six months of chemotherapy, leading to significant bone loss by the end of one year. The study suggests that earlier intervention with calcium, vitamin D, weight-bearing exercise, and counseling may help prevent bone loss in these patients.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
A clinical trial testing tin-117m DTPA, a nuclear medicine compound, may provide non-sedating pain relief and treatment for advanced-stage bone cancer. The therapy has shown promising results in easing pain for over 75% of patients, with relief lasting up to a year.
A study by Memorial Sloan-Kettering Cancer Center found that 77% of adult AML patients who received a T-cell depleted bone marrow transplant were cancer-free after 6 years. The treatment limits graft-versus-host disease risk and leukemic recurrence.